3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Conditions
Prostatic Neoplasms
3
Lung Neoplasms
2
Disease
2
Colorectal Neoplasms
2
Acute Kidney Injury
2
Urinary Bladder Neoplasms
1
Tuberous Sclerosis
1
Smoldering Multiple Myeloma
1
Salivary Gland Adenoma, Pleomorphic
1
Renal Insufficiency
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Monoclonal Gammopathy of Undetermined Significance
1
Lymphangioleiomyomatosis
1
Kidney Neoplasms
1
Hemangiosarcoma
1
Glioma
1
Gallbladder Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Pancreatic Ductal
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Sirolimus
9
Everolimus
3
Imatinib Mesylate
2
temsirolimus
1
saracatinib
1
nintedanib
1
carbon-11 acetate
1
Valproic Acid
1
Urination
1
Sugars
1
Simvastatin
1
Resveratrol
1
Respiratory Function Tests
1
Phlebotomy
1
Loratadine
1
Letrozole
1
Immunoglobulin G
1
Hydroxychloroquine
1
Glutamine
1
Genetic Testing
1
Doxycycline
1
Disulfides
1
Cetuximab
1
Celecoxib
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Lymphangioleiomyomatosis
×
Urination
×
Clear all
NCT05323370
2023-03-29
LAM-CAK
University Hospital, Tours
Completed
19 enrolled